This study will recruit 2,634 participants,50 years of age or older, who have sustained a primary fragility fracture of the hip, femur, pelvis, clinical spine, humerus, or wrist in the last 12 months. Participants will be recruited from approximately 20 sites around the United States. Patients will be randomized to either continue treatment with "Augmented Fracture Liaison Service" or to continue with "Enhanced Usual Care." Both pathways incorporate patient education about the high risk of future fractures and available treatment approaches for fracture risk reduction. Patient education materials, in English or Spanish, will include information about fractures, bone health and osteoporosis, and will refer participants to resources to provide additional education on ways to reduce the risk of another fracture. Both arms of the study will be mailed education materials after enrollment. Study participation will consist of surveys over the course of 2 years, and a visit to a bone health specialist.

This research explores how ultrasound, a common medical imaging tool, can be used to look at the ligaments that support the base of the thumb. These ligaments are important because they help the thumb stay stable during everyday tasks like opening jars, writing, or buttoning clothes. When these ligaments become weak or damaged, it can cause pain and lead to joint problems like arthritis. Right now, it's not easy for doctors to check the condition of these ligaments without advanced scans or surgery. By using ultrasound, which is safe and non-invasive, we hope to find a quicker and easier way to examine ligament health.

This study is designed to assess the 10-year post-surgery implant survivorship of Total Knee Arthroplasty (TKA) procedures performed using the LEGION Medial stabilized insert, which is FDA approved. Implant survivorship is defined as all of the knee-implanted components without a need for a revision. Questionnaires will be used up to 10 years after surgery to find more about the safety and performance of the device.

The purpose of this study is to determine the clinical efficacy of a novel, bioresorbable hydrogel sheet and wetting solution, VersaWrap®, in surgeries of the foot and ankle. This is a prospective, multi-center, controlled case series with patients identified by the Investigator in his practice. Patients who are scheduled to have procedures of the Achilles tendon will be reviewed to determine if they meet the inclusion/exclusion criteria. If eligible, patients may be enrolled in the study, and the operative surgeon will use VersaWrap® during the procedure. Patients are considered enrolled when VersaWrap® is placed intraoperatively. VersaWrap® has received its FDA 510(k) clearance. Enrollment is expected to take approximately 1-2 years. All subjects will be followed for 1 year post-operatively for a total study duration of approximately 3 years. Study follow-up visits will occur at 6 weeks, 3 months, 6 months, and 1 year after surgery. Patients enrolled in this study are receiving a standard of care surgical procedure (with or
without VersaWrap) and therefore there is no increased risk of the surgical procedure when participating in the study. The study collects patient data, and therefore there is a risk data privacy loss. Patients will also receive remuneration for their participation.